Antti Haapalinna - Concepedia

Author

Antti Haapalinna

Orion Corporation (Finland)ORCID

Also Known As

A HAAPALINNA, A Haapalinna, A. Haapalinna, Antti Haapalinna, Atte Haapalinna

112

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Orion Corporation (Finland)University of Eastern Finland Orion Corporation (United Kingdom)University of Turku Kuopio University Hospital

About

Antti Haapalinna is an author at Orion Corporation (Finland) specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	46	2.1K
2	Social Sciences	25	37	1.7K
3	Health Sciences	4	4	151
4	Education	2	2	43
5	Engineering	2	2	43

Antti Haapalinna

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Adrenergic α<sub>2C</sub>-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice Jukka Sallinen, Antti Haapalinna, Timo Viitamaa, Journal of Neuroscience PsychopharmacologyTargeted InactivationSocial SciencesNeuroendocrine MechanismBrain Dopamine	1998	214
Genetic Alteration of α2C-Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective α2-Adrenoceptor Agonist Jukka Sallinen, Richard E. Link, Antti Haapalinna, Molecular Pharmacology	1997	170
Neuroprotective Effects of Dexmedetomidine in the Gerbil Hippocampus after Transient Global Ischemia Johanna Kuhmonen, J Pokorný, Riitta Miettinen, Anesthesiology	1997	146
Genetic alteration of the α2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels Jukka Sallinen, Antti Haapalinna, Ewen MacDonald, Molecular Psychiatry Clinical DisordersStress HormoneBehavioral NeuroscienceStressPhysiology	1999	125
Neuroprotection by the α2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia Jukka Jolkkonen, Kirsi Puurunen, Jari Koıstınaho, European Journal of Pharmacology NeurophysiologyMedicineNeuropharmacologySocial SciencesBrain Injury	1999	115
An α2-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats Kirsi Puurunen, Jukka Jolkkonen, Jouni Sirviö, Neuropharmacology PharmacotherapyFocal Cerebral IschemiaSocial Sciencesα2-Adrenergic AntagonistCerebral Vascular Regulation	2001	96
Pharmacological characterization and CNS effects of a novel highly selective<i>α</i><sub>2C</sub>‐adrenoceptor antagonist JP‐1302 Jukka Sallinen, Iisa P. J. Höglund, Mia Engström, British Journal of Pharmacology	2007	94
Behavioral effects of the α2-adrenoceptor antagonist, atipamezole, after focal cerebral ischemia in rats Jukka Jolkkonen, Kirsi Puurunen, Sanna Rantakömi, European Journal of Pharmacology PharmacotherapyFocal Cerebral IschemiaExperimental PharmacologySocial SciencesCerebral Vascular Regulation	2000	94
Evaluation of the α2C-adrenoceptor as a neuropsychiatric drug target Mika Scheinin, Jukka Sallinen, Antti Haapalinna Life Sciences Molecular PharmacologyPsychiatryMedicineNeuroendocrine DisorderPsychopharmacology	2001	87
Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamezole, on α1- and α2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine Antti Haapalinna, Timo Viitamaa, Ewen MacDonald, Naunyn-Schmiedeberg s Archives of Pharmacology Molecular PharmacologyBehavioral NeuroscienceMedicineBehavioural PharmacologyBehavioral Pharmacology	1997	86

Page 1